| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 631 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 15,959 | $16.96 | $270,593.02 | -14.4% | +2.5% | - | |
| Apr 1, 2026 | CGEN Compugen Ltd. | Levine Zurit | SVP, Business Development | Sell | 3,500 | $2.20 | $7,700.00 | -10.6% | -5.0% | - | |
| Apr 1, 2026 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 679 | $16.00 | $10,864.00 | -15.8% | +9.0% | - | |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $49.33 | $739,912.32 | -1.2% | +79.7% | - | |
| Apr 1, 2026 | VIR Vir Biotechnology, Inc. | Sato Vicki L73 | Director | Sell | 22,000 | $9.07 | $199,617.00 | -2.0% | +11.2% | - | |
| Apr 1, 2026 | ERAS Erasca, Inc. | Garner Ebun | Chief Legal Officer | Sell | 80,000 | $16.40 | $1,312,000.00 | -76.1% | -3.6% | - | |
| Apr 1, 2026 | BEAM Beam Therapeutics Inc. | Ciaramella Giuseppe77 | President | Sell | 11,810 | $24.58 | $290,289.80 | -5.1% | +43.7% | - | |
| Apr 1, 2026 | BEAM Beam Therapeutics Inc. | Cavanagh Bethany J46 | SVP, Finance And Treasurer | Sell | 3,242 | $24.58 | $79,688.36 | -6.0% | +43.7% | - | |
| Apr 1, 2026 | PTCT Ptc Therapeutics, Inc. | Almstead Neil Gregory52 | Chief Technical Ops Officer | Sell | 52,003 | $69.04 | $3,590,242.77 | -21.2% | +22.8% | - | |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | Sell | 7,958 | $50.00 | $397,900.00 | -100% | +79.7% | - | |
| Apr 1, 2026 | BEAM Beam Therapeutics Inc. | Bellon Christine58 | Chief Legal Officer | Sell | 5,956 | $24.58 | $146,398.48 | -5.1% | +43.7% | - | |
| Apr 1, 2026 | SYRE Spyre Therapeutics, Inc. | Burrows Scott L74 | Chief Financial Officer | Sell | 7,500 | $49.34 | $370,076.00 | -3.7% | +79.7% | - | |
| Apr 1, 2026 | CGEN Compugen Ltd. | Ophir Eran | President And CEO | Sell | 5,625 | $2.21 | $12,412.69 | -33.1% | -5.0% | - | |
| Mar 31, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | Lederman Seth | Chief Executive Officer | Buy | 5,000 | $12.62 | $63,100.00 | +33.3% | -3.9% | - | |
| Mar 31, 2026 | KRRO Korro Bio, Inc. | Lynx1 Capital Management LP45 | 10% Owner | Buy | 520 | $10.60 | $5,512.00 | - | +12.2% | - | |
| Mar 31, 2026 | ABEO Abeona Therapeutics Inc. | Seshadri Vishwas80 | Chief Executive Officer | Sell | 29,985 | $4.38 | $131,481.23 | -2.1% | +25.2% | - | |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. | Soteropoulos Paula75 | Director | Sell | 599 | $80.11 | $47,985.89 | -100% | +13.6% | - | |
| Mar 31, 2026 | COGT Cogent Biosciences, Inc. | Fairmount Funds Management LLC73 | Director | Sell | 7,000,000 | $34.66 | $242,620,000.00 | -56.0% | -1.0% | - | |
| Mar 31, 2026 | EWTX Edgewise Therapeutics, Inc. | Donovan Joanne M.49 | CMO | Sell | 21,338 | $32.12 | $685,308.28 | -69.0% | +31.6% | - | |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. | Savitz Ryan | EVP, CFO &Cbo | Sell | 114,367 | $83.00 | $9,492,595.50 | -18.5% | +13.6% | - | |
| Mar 31, 2026 | ZBIO Zenas Biopharma, Inc. | Moulder Leon O Jr79 | Chief Executive Officer | Buy | 54,000 | $18.91 | $1,021,140.00 | +1.6% | +32.3% | - | |
| Mar 31, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 57,180 | $13.14 | $751,302.98 | -3.0% | +51.0% | - | |
| Mar 30, 2026 | ANAB Anaptysbio, Inc. | Schmid John P.80 | Director | Sell | 20,645 | $56.11 | $1,158,451.42 | -16.6% | +71.0% | - | |
| Mar 30, 2026 | WVE Wave Life Sciences Ltd. | Ra Capital Management, L.P.53 | Director, 10% Owner | Buy | 8,772,496 | $6.23 | $54,624,377.99 | +9.7% | -11.9% | - | |
| Mar 27, 2026 | EWTX Edgewise Therapeutics, Inc. | Donovan Joanne M.49 | CMO | Sell | 16,358 | $30.98 | $506,734.85 | -38.7% | +35.2% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.